Treventis was well represented at the Alzheimer Association International Conference, running from Jul 22-26, 2018, in Chicago, Illinois. In attendance were CEO Christopher Barden; CSO Mark Reed; Chief Medical Officer Dr. Donald Weaver, and Treventis Diagnostics head Dr. Sultan Darvesh.
Dr. Weaver presented a poster entitled “Optimization of a Murine CNS IDO1 Pharmacokinetic-Pharmacodynamic Model Using Systemic LPS Administration.” In this work, Dr. Weaver’s research group – in collaboration with Treventis scientists Kurt Stover, Seung-Pil Yang, and Mark Reed – explored the potential modulation of neuroinflammation in Alzheimer’s disease by optimizing a pharmacokinetic-pharmacodynamic (PK/PD) model of IDO1 using systemic administration of LPS in mice. This work established that systemic administration of LPS is a useful model for evaluating levels of tryptophan and its metabolite in the brain, which can drive the selection of new IDO1 therapeutic compounds for brain diseases.
Dr. Darvesh presented a study on butyrylcholinesterase genetic polymorphism and neuroimaging biomarkers in Alzheimer’s Disease. 615 participants were genotypes for BCHE-K and 785 for BCHE-A, two genetic variants that result in decreased BCHE expression. These participants were stratified into control, mild cognitive impairment or Alzheimer’s disease groups. The work concluded that standard structural, metabolic and molecular biomarkers are not strongly affected by BCHE-K or BCHE-A. Altogether, 615 participants were genotyped for BCHE-K and 785 – for BCHE-A (each stratified into control, mild cognitive impairment or Alzheimer’s Disease groups). Further work will focus on uncovering potential characteristic regional changes among these variants in Alzheimer’s disease.